The multi-kinase inhibitor afatinib serves as a novel candidate for the treatment of human uveal melanoma.
Wenying ShuXue ZhuKe WangSvetlana CherepanoffR Max ConwayMichele C MadiganHong ZhuLing ZhuMichael MurrayFanfan ZhouPublished in: Cellular oncology (Dordrecht) (2022)
Our data indicate that afatinib activates UM cell death and targets the HER2-mediated cascade, which modulates STAT1-Bcl-xL/cyclin D1 signalling. Thus, targeting HER2 with agents like afatinib may be a novel therapeutic strategy to treat UM and to prevent metastasis.
Keyphrases
- cell death
- epidermal growth factor receptor
- advanced non small cell lung cancer
- endothelial cells
- cell cycle arrest
- cell cycle
- electronic health record
- cancer therapy
- induced pluripotent stem cells
- pluripotent stem cells
- big data
- machine learning
- tyrosine kinase
- combination therapy
- data analysis
- skin cancer
- artificial intelligence
- deep learning
- smoking cessation